Menu
Search
|

Menu

Close
X

Minerva Neurosciences Inc NERV.OQ (NASDAQ Stock Exchange Global Market)

8.28 USD
-- (--)
As of Nov 14
chart
Previous Close 8.28
Open --
Volume --
3m Avg Volume 54,753
Today’s High --
Today’s Low --
52 Week High 12.95
52 Week Low 4.90
Shares Outstanding (mil) 38.87
Market Capitalization (mil) 316.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.954
FY17
-1.081
FY16
-0.985
FY15
-1.163
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
--
22.95
Price to Book (MRQ)
vs sector
3.12
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
0.00
15.47
LT Debt to Equity (MRQ)
vs sector
0.00
11.13
Return on Investment (TTM)
vs sector
-27.88
13.00
Return on Equity (TTM)
vs sector
-39.91
14.69

EXECUTIVE LEADERSHIP

Remy Luthringer
Executive Chairman of the Board, Chief Executive Officer, Since 2018
Salary: $213,761.00
Bonus: $50,000.00
Richard Russell
President, Since 2017
Salary: --
Bonus: --
Geoffrey Race
Executive Vice President and Chief Financial Officer, Since 2014
Salary: $210,000.00
Bonus: $175,000.00
Joseph Reilly
Chief Operating Officer, Vice President, Since 2014
Salary: --
Bonus: --
Frederick Ahlholm
Chief Accounting Officer, Vice President, Since 2014
Salary: $154,583.00
Bonus: $75,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1601 Trapelo Rd Ste 286
WALTHAM   MA   02451-7337

Phone: +1617.6007373

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

SPONSORED STORIES